-
DE
Non-Hodgkin lymphoma is a diverse group of blood cancers affecting the lymphatic system. Abnormal lymphocytes multiply uncontrollably, leading to various clinical presentations.
Non-Hodgkin lymphoma is a diverse group of blood cancers affecting the lymphatic system. Abnormal lymphocytes multiply uncontrollably, leading to various clinical presentations.
Non-Hodgkin lymphoma (NHL) refers to a large and diverse group of malignant cancers that originate in the lymphatic system. Unlike Hodgkin lymphoma, NHL lacks the characteristic Reed-Sternberg cells. The disease arises from malignant lymphocytes – white blood cells of the immune system – and can affect both B-lymphocytes and T-lymphocytes. NHL encompasses more than 60 distinct subtypes, which differ considerably in their behavior, treatment, and prognosis.
The exact causes of Non-Hodgkin lymphoma are not fully understood in many cases. Several factors are known to increase the risk:
Symptoms of Non-Hodgkin lymphoma can vary depending on the subtype and extent of the disease. Common signs include:
Diagnosing NHL requires a combination of investigative methods:
NHL is classified according to the Ann Arbor classification into four stages (I to IV), depending on how widely the disease has spread throughout the body. A further distinction is made between indolent (slow-growing) and aggressive (fast-growing) lymphomas.
Treatment depends on the subtype, stage, and overall health of the patient. The main treatment options include:
Chemotherapy is frequently the cornerstone of NHL treatment. A widely used regimen is R-CHOP, which combines rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
Rituximab is a monoclonal antibody that specifically targets the CD20 protein on B-lymphocytes, destroying these cells. It is used in many B-cell lymphomas.
For locally confined disease or as consolidation after chemotherapy, radiation therapy may be applied.
For relapsed or refractory NHL, autologous or allogeneic stem cell transplantation may be considered.
Newer approaches include targeted therapies (e.g., BTK inhibitors such as ibrutinib) and the innovative CAR T-cell therapy, in which a patient's own T cells are genetically modified to specifically attack lymphoma cells.
For indolent lymphomas without disease-related symptoms, an initial watch-and-wait approach may be justified.
Prognosis depends strongly on the subtype, stage, and response to therapy. Aggressive NHL often responds well to intensive chemotherapy and can be cured in many cases. Indolent NHL follows a chronic course and is frequently not curable, but can be controlled for many years. Modern treatment approaches have significantly improved survival rates.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.